BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 12/13/21

BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve Pre-specified and post hoc analyses show NurOwn produced clinical benefits in ALS patients with less severe disease Biomarker data show that NurOwn dr...

BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing PR Newswire NEW YORK and SOMERSET, N.J. , Dec. 7, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer ...

BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND Biomarker data suggest that NurOwn drives significant changes on multiple biomarkers across ALS disease pathways which may be important in achieving clinical outc...

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium Pre-specified and post hoc analyses leveraging the published ENCALS model demonstrate a potential treatment effect o...

Brainstorm Cell Therapeutics Inc. (BCLI) Q3 2021 Earnings Conference Call Nov 15, 2021 08:00 AM ET Company Participants Michael Rice - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Stacy Lindborg - E...

BrainStorm Cell Therapeutics (NASDAQ:BCLI): Q3 GAAP EPS of -$0.51 misses by $0.31. Cash, cash equivalents, and short-term bank deposits were approximately $28M as of September 30, 2021, compared to approximately $35M on June 30, 2021. Press Release For further details see: BrainStorm Ce...

BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update BrainStorm remains committed to pursuing the best and most expeditious path forward to facilitate access to NurOwn® for people living with ALS Presented important...

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is scheduled to announce Q3 earnings results on Monday, November 15th, before market open. The consensus EPS Estimate is -$0.20 For further details see: BrainStorm Cell Therapeutics Q3 2021 Earnings Preview

ACM, ACRX, ADN, AMPY, AVPT, AYRO, BCLI, BFLY, CLSN, OTCQB:CVSI, FREY, GMDA, GOED, KALA, MICT, OEG, ONDS, OTLY, PLX, PTN, RAIL, SOHU, TLS, TRVN, TSN, VBLT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs Sidney A. Spector, MD, PhD, appointed Senior VP, Global Strategy and Medical Affairs Kim Thacker, MD, appointed Senior VP, Medical Affairs and Clinical Innovation Sta...